OncoMatch/Clinical Trials/NCT02889666
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
Is NCT02889666 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for recurrent non-small cell lung cancer.
Treatment: Cisplatin · Carboplatin · Docetaxel · Gemcitabine/Carboplatin · Gemcitabine/Cisplatin · Docetaxel/Oxaliplatin · Docetaxel/Carboplatin — The purpose of this study is to determine if the commonly administered chemotherapeutic agents including cisplatin, carboplatin, oxaliplatin, docetaxel and gemcitabine for solid tumors in clinical oncology, either a single format or given as combinations followed by surgery are effective in the treatment of relapsed and refractory non-small cell lung cancer patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage ≥ IA (T1A, N0, M0) (1997 revision of the International Union Against Cancer TNM staging system)
Excluded: Stage IV
A Clinical Stage ≥ IA (T1a, N0, M0) of lung disease but without diagnosed distant metastasis (according to the 1997 revision of the International Union Against Cancer TNM staging system)
Performance status
WHO 0–1
Prior therapy
Cannot have received: cancer chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify